World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
84
Citations
28625
World Ranking
15003
National Ranking
7584

B. Douglas Smith publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where B. Douglas Smith sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 370 publications — 32nd percentile

32% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

B. Douglas Smith D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where B. Douglas Smith sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 84 D-Index — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

B. Douglas Smith is affiliated with Johns Hopkins University in the United States and has a robust research presence in the field of medicine, with a particular focus on hematology. Their research covers a broad range of subfields, including genetics, molecular biology, public health, environmental and occupational health, and oncology.

The primary topics in their work emphasize leukemia research, especially acute myeloid leukemia and chronic myeloid leukemia treatments. Other research areas include chronic lymphocytic leukemia, acute lymphoblastic leukemia, myeloproliferative neoplasms relating to diagnosis and treatment, retinoids in leukemia and cellular processes, and eosinophilic disorders and syndromes.

B. Douglas Smith's publication record includes papers in several notable venues. The most frequent journals where their work appears include:

  • Blood
  • Clinical Lymphoma Myeloma & Leukemia
  • Leukemia Research
  • Leukemia
  • Clinical Cancer Research

Key recent papers authored or co-authored by B. Douglas Smith include:

  • Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology (2020), Journal of the National Comprehensive Cancer Network
  • Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia (2021), Blood Cancer Discovery
  • Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology (2024), Journal of the National Comprehensive Cancer Network
  • Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study (2020), Leukemia
  • Myeloablative haploidentical BMT with posttransplant cyclophosphamide for hematologic malignancies in children and adults (2020), Blood Advances

Their frequent co-authors include Gabriel Ghiaur, Amy E. DeZern, Mark J. Levis, Ivana Gojo, and Jonathan Webster, reflecting ongoing collaborative work in hematology and leukemia research.

Best Publications

  • Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase.

    Donald B. Smith;Kevin S. Johnson

  • Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource

    Donald B. Smith;Jens Bukh;Carla Kuiken;A. Scott Muerhoff

  • Characterization of clonogenic multiple myeloma cells

    William H Matsui;Carol Ann Huff;Qiuju Wang;Matthew T Malehorn

  • ICTV Virus Taxonomy Profile: Flaviviridae.

    Peter Simmonds;Paul Becher;Jens Bukh;Ernest A. Gould

  • Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

    B. Douglas Smith;Mark Levis;Mark Levis;Miloslav Beran;Miloslav Beran;Francis Giles;Francis Giles

  • Consensus proposals for classification of the family Hepeviridae

    Donald B. Smith;Peter Simmonds;Shahid Jameel

  • Nonmuscle Actin-Binding Proteins

    Stossel Tp;Chaponnier C;Ezzell Rm;Hartwig Jh

  • Clonogenic Multiple Myeloma Progenitors, Stem Cell Properties, and Drug Resistance

    William Matsui;Qiuju Wang;James P. Barber;Sarah Brennan

  • Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: proposals for standardization

    B Robertson;G Myers;C Howard;T Brettin

  • A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

    Mark Levis;Jeffrey Allebach;Kam-Fai Tse;Rui Zheng

  • Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

    Steven D. Gore;Stephen Baylin;Elizabeth Sugar;Hetty E. Carraway

  • High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease.

    Leo Luznik;Javier Bolaños-Meade;Marianna Zahurak;Allen R. Chen

  • Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse

    Mark Levis;Farhad Ravandi;Eunice S. Wang;Maria R. Baer

  • Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

    Jorge E. Cortes;Florian H. Heidel;Andrzej Hellmann;Walter Fiedler

  • Identification of genotypes of hepatitis C virus by sequence comparisons in the core, E1 and NS-5 regions

    P. Simmonds;D. B. Smith;F. McOmish;P. L. Yap

  • Proposed reference sequences for hepatitis E virus subtypes

    Donald B. Smith;Peter Simmonds;Jacques Izopet;Edmilson F. Oliveira-Filho

  • The origin of hepatitis C virus genotypes

    Donald B. Smith;Steve Pathirana;Fiona Davidson;Emer Lawlor

  • Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide

    Shannon R. McCurdy;Jennifer A. Kanakry;Margaret M. Showel;Hua Ling Tsai

  • Variation of the hepatitis C virus 5′ non-coding region: implications for secondary structure, virus detection and typing

    Donald B. Smith;Janet Mellor;Lisa M. Jarvis;Fiona Davidson

  • Immunoablative High-Dose Cyclophosphamide without Stem-Cell Rescue for Refractory, Severe Autoimmune Disease

    Robert A. Brodsky;Michelle Petri;B. Douglas Smith;Eric J. Seifter

Frequent Co-Authors

Judith E. Karp
Judith E. Karp Johns Hopkins University
Richard J. Jones
Richard J. Jones Johns Hopkins University
Mark J. Levis
Mark J. Levis Johns Hopkins University
Peter Simmonds
Peter Simmonds University of Oxford
Leo Luznik
Leo Luznik Johns Hopkins University
Michael A. McDevitt
Michael A. McDevitt Johns Hopkins University
Richard F. Ambinder
Richard F. Ambinder Johns Hopkins University
Ephraim J. Fuchs
Ephraim J. Fuchs Johns Hopkins University
Allan D. Hess
Allan D. Hess Johns Hopkins University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're exploring a career in Medicine but seeking alternative or accelerated routes, there are several online degree options to consider. Nursing remains one of the most popular pathways, offering flexibility and accessibility for aspiring healthcare professionals.

For registered nurses looking to advance their credentials affordably, many schools offer the cheapest rn to bsn programs online. These programs enable working nurses to earn their Bachelor of Science in Nursing at a lower cost while continuing to work.

Prospective students without a nursing background but who want to enter the profession quickly can explore online direct entry msn programs. These allow those with a non-nursing bachelor’s degree to earn a Master of Science in Nursing in less time.

Applicants in search of less competitive admissions may prefer one of the easiest rn program options, which can increase the chances of starting a nursing career sooner.

Beyond nursing, allied health careers such as medical billing and coding are also in demand. You can find information about financial aid for medical billing and coding online classes, making this pathway even more accessible for those seeking a healthcare career without direct patient care.

Best Scientists Citing B. Douglas Smith

Trending Scientists

Recently Published Articles